Gernot Kleinberger

Gernot Kleinberger

Auto-generated profile, based on publicly available information

Gernot Kleinberger

Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
MSMarc Suárez-Calvet
Marc Suárez-Calvet
EMEstrella Morenas-Rodríguez
Estrella Morenas-Rodríguez
GKGernot Kleinberger
Gernot Kleinberger
KSKai Schlepckow
Kai Schlepckow
CHChristian Haass
Christian Haass
TREM2 is a transmembrane receptor that is predominantly expressed by microglia in the central nervous system. Rare variants in the TREM2 gene increase the risk for late-onset Alzheimer’s disease (AD). Soluble TREM2 (sTREM2) resulting from shedding of the TREM2 ectodomain can be detected in the cerebrospinal fluid (CSF) and is a surrogate measure of TREM2-mediated microglia function. CSF sTREM2 has been previously reported to increase at different clinical stages of AD, however, alterations in relation to Amyloid β-peptide (Aβ) deposition or additional pathological processes in the amyloid cascade (such as tau pathology or neurodegeneration) remain unclear. In the current cross-sectional study, we employed the biomarker-based classification framework recently proposed by the NIA-AA consensus guidelines, in combination with clinical staging, in order to examine the CSF sTREM2 alterations at early asymptomatic and symptomatic stages of AD. A cross-sectional study of 1027 participants of the Alzheimer’s Disease Imaging Initiative (ADNI) cohort, including 43 subjects carrying TREM2 rare genetic variants, was conducted to measure CSF sTREM2 using a previously validated enzyme-linked immunosorbent assay (ELISA). ADNI participants were classified following the A/T/N framework, which we implemented based on the CSF levels of Aβ1-42 (A), phosphorylated tau (T) and total tau as a marker of neurodegeneration (N), at different clinical stages defined by the clinical dementia rating (CDR) score. CSF sTREM2 differed between TREM2 variants, whereas the p.R47H variant had higher CSF sTREM2, p.L211P had lower CSF sTREM2 than non-carriers. We found that CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, we observed decreased CSF sTREM2 levels at the earliest asymptomatic phase when only abnormal Aβ pathology (A+) but no tau pathology or neurodegeneration (TN-), is present. Aβ pathology (A) and tau pathology/neurodegeneration (TN) have differing associations with CSF sTREM2. While tau-related neurodegeneration is associated with an increase in CSF sTREM2, Aβ pathology in the absence of downstream tau-related neurodegeneration is associated with a decrease in CSF sTREM2.

8 May 2017 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
FMFargol Mazaheri
Fargol Mazaheri
NSNicolas Snaidero
Nicolas Snaidero
GKGernot Kleinberger
Gernot Kleinberger
CMCharlotte Madore
Charlotte Madore
ADAnna Daria
Anna Daria
CHChristian Haass
Christian Haass

10 March 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KSKai Schlepckow
Kai Schlepckow
KMKathryn M Monroe
Kathryn M Monroe
GKGernot Kleinberger
Gernot Kleinberger
LCLudovico Cantuti‐Castelvetri
Ludovico Cantuti‐Castelvetri
SPSamira Parhizkar
Samira Parhizkar
CHChristian Haass
Christian Haass
Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease‐associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full‐length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., α‐secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for α‐secretase‐mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho‐SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid β‐peptide in vitro . In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9‐bound. Moreover, in a mouse model for Alzheimer's disease‐related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease‐associated state.

30 August 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KSKai Schlepckow
Kai Schlepckow
GKGernot Kleinberger
Gernot Kleinberger
AFAkio Fukumori
Akio Fukumori
RFRegina Feederle
Regina Feederle
SLStefan F Lichtenthaler
Stefan F Lichtenthaler
CHChristian Haass
Christian Haass
Sequence variations occurring in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) support an essential function of microglia and innate immunity in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. TREM2 matures within the secretory pathway, and its ectodomain is shed on the plasma membrane. Missense mutations in the immunoglobulin (Ig)‐like domain such as p.T66M and p.Y38C retain TREM2 within the endoplasmic reticulum and reduce shedding as well as TREM2‐dependent phagocytosis. Using mass spectrometry, we have now determined the cleavage site of TREM2. TREM2 is shed by proteases of the ADAM (a disintegrin and metalloproteinase domain containing protein) family C‐terminal to histidine 157, a position where an AD‐associated coding variant has been discovered (p.H157Y) in the Han Chinese population. Opposite to the characterized mutations within the Ig‐like domain, such as p.T66M and p.Y38C, the p.H157Y variant within the stalk region leads to enhanced shedding of TREM2. Elevated ectodomain shedding reduces cell surface full‐length TREM2 and lowers TREM2‐dependent phagocytosis. Therefore, two seemingly opposite cellular effects of TREM2 variants, namely reduced versus enhanced shedding, result in similar phenotypic outcomes by reducing cell surface TREM2.

30 May 2017 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
GKGernot Kleinberger
Gernot Kleinberger
MBMatthias Brendel
Matthias Brendel
EMEva Mracsko
Eva Mracsko
BWBenedikt Wefers
Benedikt Wefers
LGLinda Groeneweg
Linda Groeneweg
CHChristian Haass
Christian Haass

10 August 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MEMichael Ewers
Michael Ewers
GBGloria Biechele
Gloria Biechele
MSMarc Suárez‐Calvet
Marc Suárez‐Calvet
CSChristian Sacher
Christian Sacher
TBTanja Blume
Tanja Blume
NFNicolai Franzmeier
Nicolai Franzmeier
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18 F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.